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Overexpression of Glyoxalase-I in Bovine Endothelial Cells Inhibits Intracellular
Advanced Glycation Endproduct Formation and Prevents Hyperglycemia-induced
Increases in Macromolecular Endocytosis
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and Michael Brownlee*
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§
Department of Medicine, Endocrine-Metabolism Division, Dartmouth Medical School, Hanover, New Hampshire 03755; and
i
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Abstract
Methylglyoxal (MG), a dicarbonyl compound produced by the
fragmentation of triose phosphates, forms advanced glycation endproducts (AGEs) in vitro. Glyoxalase-I catalyzes the
conversion of MG to S-D-lactoylglutathione, which in turn is
converted to D-lactate by glyoxalase-II. To evaluate directly
the effect of glyoxalase-I activity on intracellular AGE formation, GM7373 endothelial cells that stably express human glyoxalase-I were generated. Glyoxalase-I activity in
these cells was increased 28-fold compared to neo-transfected control cells (21.8060.1 vs. 0.7660.02 mmol/min/mg
protein, n 5 3, P , 0.001). In neo-transfected cells, 30 mM
glucose incubation increased MG and D-lactate concentration approximately twofold above 5 MM (35.565.8 vs.
19.661.6, P , 0.02, n 5 3, and 21.061.3 vs. 10.061.2 pmol/
106 cells, n 5 3, P , 0.001, respectively). In contrast, in glyoxalase-I–transfected cells, 30 mM glucose incubation did not
increase MG concentration at all, while increasing the enzymatic product D-lactate by . 10-fold (18.963.2 vs. 18.46
5.8, n 5 3, P 5 NS, and 107.169.0 vs. 9.460 pmol/106 cells,
n 5 3, P , 0.001, respectively). After exposure to 30 mM
glucose, intracellular AGE formation in neo cells was increased 13.6-fold (2.5860.15 vs. 0.1960.03 total absorbance
units, n 5 3, P , 0.001). Concomitant with increased intracellular AGEs, macromolecular endocytosis by these cells
was increased 2.2-fold. Overexpression of glyoxalase-I completely prevented both hyperglycemia-induced AGE formation and increased macromolecular endocytosis. (J. Clin.
Invest. 1998. 101:1142–1147.) Key words: advanced glycation
endproducts • methylglyoxal • glyoxalase-I • cell lines • endocytosis

Introduction
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ship between hyperglycemia and diabetic macrovascular disease is also supported by recent literature (2, 3). The mechanisms by which hyperglycemia may damage vascular cells
include increased polyol pathway flux associated with myoinositol depletion and decreased Na/K ATPase activity (4), alterations in redox state (5), synthesis of diacylglycerol with activation of the protein kinase C BII isoform (6), production of
reactive oxygen species (7), and nonenzymatic modification of
proteins by glucose-derived advanced glycation endproducts
(AGEs)1 (8, 9). Recently, we have shown that AGEs accumulate much more rapidly inside endothelial cells than they do on
extracellular proteins, increasing 13.8-fold after only 1 wk of
incubation in high glucose-containing media (10). This observation suggests that inside cells, highly reactive AGE precursors are generated at a faster rate than outside cells, perhaps
from glycolytic intermediates that are uniquely present in cells.
In model systems, AGEs have been shown to arise from both
metal-catalyzed autoxidation of glucose with the dicarbonyl
glyoxal and arabinose as intermediates (11), and from decomposition of the Amadori product to the reactive dicarbonyl
3-deoxyglucosone (3-DG) (12). The dicarbonyl methylglyoxal
(MG), produced by nonenzymatic fragmentation of triose phosphates, also forms AGEs in vitro, and has been postulated to
be a major source of intracellular and plasma AGEs (13) (Fig. 1).
MG is efficiently metabolized by the glyoxalase system,
where MG is first converted by glyoxalase-I to S-D-lactoylglutathione in the presence of reduced glutathione as an essential
cofactor, and then converted to D-lactate by glyoxalase-II. MG
can also be converted into the AGE precursor acetol by the
enzyme aldose reductase, although the kcat/Km is . 100-fold
less than for glyoxalase-I (14, 15). In situ activity of glyoxalase-I in human tissue calculated from measured enzyme protein concentrations and kinetic constants is 10–40 times higher
than that of aldose reductase for all tissue except for kidney
medulla (14).
In this study, we have investigated the role of MG in intracellular AGE formation by using a glyoxalase-I inhibitor, S-[Nhydroxy-N-(4-chlorophenyl) carbamoyl] glutathione diethyl
ester (HCCG) and by generating GM7373 endothelial cells that
stably express human glyoxalase-I. The effect of glyoxalase-I
overexpression on glyoxal, 3-DG, MG, D-lactate, and acetol
was determined, as well as the effect on intracellular AGE content. Since inhibition of intracellular AGEs by aminoguanidine
1. Abbreviations used in this paper: 3-DG, 3-deoxyglucosone; AGE,
advanced glycation endproduct; bFGF, basic fibroblast growth factor;
CEL, carboxyethyllysine; CML, carboxymethyllysine; HCCG, S-[Nhydroxy-N-(4-chlorophenyl) carbamoyl] glutathione diethyl ester;
MG, methylglyoxal; TDQ, 2-(2,3,4-trihydroxybutyl)-6,7-dimethoxyquinoxaline.

Figure 1. Schematic representation of potential pathway leading to
AGE formation. AGEs arise from autoxidation of glucose to glyoxal,
decomposition of the Amadori product to 3-DG, and the glyceraldehyde fragmentation product MG, which all react with amino groups
of proteins. MG is metabolized to the unreactive D-lactate by the glyoxalase system (see Introduction for details).

has been shown to reduce hyperglycemia-induced increases in
macromolecular endocytosis, the effect of glyoxalase-I overexpression on this phenomenon was also investigated (16).

Methods
Cell culture conditions. Transformed fetal bovine aortic endothelial
cells, GM7373 cells (17), were obtained from the National Institute of
General Medical Sciences Human Genetic Mutant Cell Repository
(Camden, NJ). The cells were maintained in MEM containing 10%
fetal bovine serum, essential and nonessential amino acids, and antibiotics, but no insulin. Confluent cells used for experiments were incubated in MEM containing 0.4% fetal bovine serum (growth arrest
conditions) to mimic the state of endothelial cells in vivo, with either
5 or 30 mM glucose for 7 d. Culture medium was changed twice daily,
and glucose concentration was measured before each change of medium using a glucose analyzer (Beckman, Brea, CA). Cell viability was
checked using methylene blue exclusion. There was no change in viability under any of the experimental conditions over the 7-d period. The
media and all supplements were purchased from Gibco (Grand Island,
NY). GM7373 cells were also incubated with 40 mM of the glyoxalase-I inhibitor, HCCG (18) (gift of Dr. D.J. Creighton, Department
of Chemistry and Biochemistry, University of Maryland, Baltimore,
MD) for 4 d with media changed twice a day. A preliminary dose–
response curve using 10, 20, 40, 80, and 100 mM of inhibitor showed
that cell viability began to decrease at a concentration of 80 mM. All experiments were performed three times with triplicate replicates.
Cell cytosol preparation. Cytosolic fractions of confluent cells

were prepared as described previously (19). Briefly, the cells were
trypsinized, lysed in PBS containing proteinase inhibitors by three cycles of freezing and thawing and sonication at 48C for 1 min, and then
centrifuged at 12,000 g for 20 min. The supernatant was used as the
cytosolic fraction.
Glyoxalase-I assay. The glyoxalase-I assay was performed according to a spectrophotometric method monitoring the increase in
absorbance at 240 nm due to the formation of S-D-lactoylglutathione
for 2 min at 258C (20). The standard assay mixture contained 7.9 mM
MG, 1 mM glutathione, 14.6 mM magnesium sulfate, and 182 mM imidazole HCl, pH 7.0. Before initiating the reaction by adding the cytosolic fraction (10–30 mg) to the assay mixture, the mixture was allowed to stand for at least 2 min to ensure the equilibration of
hemithioacetal formation. One unit of activity is defined as the formation of 1 mmol of S-D-lactoylglutathione/min/mg cell protein. Protein concentration was determined by Coomassie plus protein assay
reagent (Pierce Chemical Co., Rockford, IL).
Measurement of total intracellular AGE protein. Equal amounts
of cytosolic protein from cells incubated under different conditions
were dot blotted onto nitrocellulose membranes (Schleicher and
Schuell, Inc., Keene, NH). AGEs were detected by using the monoclonal anti-AGE antibody 6D12, which recognizes carboxymethyllysine (CML) like structures, as well as carboxyethyllysine (CEL) and
several unidentified AGE epitopes (21). The immunocomplexes were
visualized using an enhanced chemiluminescence kit (Amersham International, Amersham, UK) and evaluated by scanning densitometry using the Ultrascan XL (LKB, Uppsala, Sweden). The assay was
standardized as described previously (22). To confirm that this antibody recognized MG modified proteins, human serum albumin minimally modified by MG was assayed by immunoblotting. The minimally modified protein was made as described previously: 0.1 mM
HSA and purified MG were incubated in 0.1 M sodium phosphate
buffer, pH 7.4, at 378C for 24 h, then dialyzed extensively against Dulbecco’s modified PBS (23). Immunoblots with mAb 6D12 showed a
linear dependence on both MG-modified protein concentration and
on MG concentration when incubated with an invariant amount of
protein (data not shown). To determine whether the mAb 6D12 was
in fact detecting changes in intracellular CML, MG-derived CEL, or
an unidentified MG-derived epitope, CML and CEL were quantitated in 1.5 mg of cytosol protein by gas chromatography/mass spectrometry as described previously (24, 25) in both neo- and glyoxalaseI–transfected cells.
Measurement of macromolecular endocytosis. The endocytosis assay was performed as described previously (16). Briefly, confluent
neo and glyoxalase-I–expressing cells were exposed to either 5 or 30 mM
glucose as described. After 10 d the cells were incubated with 100 mg/ml
horseradish peroxidase type II (Sigma Chemical Co., St. Louis, MO)
for 30 min at 378C. The cells were washed thoroughly with PBS, trypsinized, and counted. Equal numbers of cells were lysed in 50-mM citrate phosphate buffer (pH 5) by sonication for 30 s. 50 ml of each cell
lysis was transferred to 96-well ELISA plates and incubated with 50 ml
of 4 mM O-phenylenediamine (Sigma Chemical Co.) and 0.004%
H2O2 in citrate phosphate buffer for 1 h at room temperature. The reaction was stopped with 0.2 M H2SO4 and the OD was read at 495 nm.
Generation of GM7373 cells that stably express human glyoxalase-I.
The human glyoxalase-I cDNA (26) was provided by Dr. Kenneth D.
Tew (Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA). A 0.6-kb fragment of the human glyoxalase-I cDNA
in PUC13 was cut out by EcoRI sites and ligated into HSVPrPuc (27–
29) digested with the same enzyme. The introduction of the pHSVPuc glyoxalase-I into the cells was performed by cotransfection with
pSV7-neo (30) using a liposome method (31). Briefly, the cells (2.5 3
106) were incubated with both 25 mg of the pHSV-Puc glyoxalase-I
and pSV7-neo in the presence of 40 ml of lipofectin (GIBCO BRL,
Gaithersburg, MD) in 2 ml of serum-free medium for 5 h. The glyoxalase-I is under the transcriptional control of the HSV immediate
early 4/5 promoter in this vector. The transfected cells were selected
against G-418 (32). The expression of the gene was demonstrated by
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both Western blotting using an antibody against human glyoxalase-I
(gift of Dr. Kenneth D. Tew) and by measuring the enzyme activity.
Immunocomplexes on the blotting membrane were visualized using
an enhanced chemiluminescence kit (Amersham International).
Measurement of a-oxoaldehydes in cells. Glyoxal (40% aqueous
solution) was purchased from Sigma Chemical Co. MG and 3-DG
were prepared, purified, and characterized as described previously
(33, 34). Stock solutions of MG and glyoxal were calibrated by end
point enzymatic assay with glyoxalase-I (35) using molar changes of
the extinction coefficient for the formation of the corresponding S-2hydroxyacylglutathione deduced from reference 36. The concentration of glyoxal, 3-DG, and MG were determined in endothelial cell
cytosol by derivatization of the a-oxoaldehydes with 1,2-diamino-4,5dimethoxybenzene using a previously described method (35, 37) with
the following modifications: samples were acidified with 100 mM acetic acid for storage at 2808C and transferred (on cardice) between
collaborating groups before derivatization to minimize degradation
of nucleotides to MG (38), the HPLC mobile phase was 20 mM ammonium formate, pH 3.4, with isocratic 30% methanol from 0 to 40
min, a linear gradient of 30–48% methanol from 40 to 60 min, 90%
methanol from 60 to 70 min for washing of the column, and reequilibration with the initial mobile phase for 5 min, and the adducts and
internal standard were detected by fluorescence (excitation wave
length 352 nm, emission wavelength 395 nm) with a scanning fluorescence detector (model 474; Waters Instruments Inc., Rochester, MN).
For 3-DG, glyoxal and MG: the retention time of derivatized adducts
was 8.5, 22.4, and 38.3 min (retention time of the internal standard
was 53.3 min), the recoveries were 52, 70, and 59%, the limits of detection (analyte concentration equivalent to 2 SDs of the intercept on
the analyte/internal standard peak area ratio) were 21, 11, and 14 pmol,
and the interbatch coefficients of variation were 15, 11, and 10% (n 5 9),
respectively. For application of the a-oxoaldehyde assay using 1,2diamino-4,5-dimethoxybenzene as a derivatizing agent for the assay
of 3-DG, the 3-DG adduct 2-(2,3,4-trihydroxybutyl)-6,7-dimethoxyquinoxaline (TDQ) was prepared, purified, and characterized. 3-DG
(72 mg, 0.4 mmol) and 1,2-diamino-4,5-dimethoxybenzene dihydrochloride (48 mg, 0.2 mmol) were dissolved in hydrochloric acid (1.5 M,
1.75 ml) and stirred under nitrogen at room temperature for 6 h. The
product mixture was neutralized to pH 7.4 by the addition of 2 M potassium bicarbonate (z 1.3 ml), filtered (0.2-mm pore size), and TDQ
purified by preparative reversed-phase HPLC. The column was a 2.5 3
8 cm ODS cartridge with a 2.5 3 1 cm precolumn, the flow rate 9.9
ml/min, the sample loading 1 ml of neutralized crude product, and the
mobile phase 20 mM acetic acid, 10% methanol (0–12 min) with a linear gradient of 10–50% methanol (12–32 min). The eluate absorbance was monitored at 352 nm. The TDQ-containing fraction, retention interval 4–16 min, was collected from three runs, pooled, and
lyophilized to dryness. TDQ was characterized: melting point 94–
958C (decomposed); 1H NMR (50% vol/vol CD3CN-D20) 8.15 (s, 1H,
H-3), 7.23 (s, 1H, H-8), 7.19 (s, 1H, H-5), 3.97 (s, 6 H, 6,7-MeO), 3.78
(ddd, 1H, H-39, JH29,H39 5 7.7 Hz, JH39,H49a 5 9.9 Hz, JH39, H49b 5
3.0 Hz), 3.76 (dd, 1H, H-19b; JH19a,H19b 5 10.1 Hz, JH19b, H29 5 7.1
Hz), 3.67 (m, 1H, H-29; JH19a,H29 5 6.4 Hz, JH19b,H29 5 7.1 Hz,
JH29,H39 5 7.7 Hz), 3.62 (dd, 1H, H-19a; JH19a,H19b 5 10.1 Hz, JH19a,
H29 5 6.4 Hz), 3.24 (dd, 1H, H-49b; JH49a,H49b 5 14.3 Hz, JH39,
H49b 5 3.0 Hz), 3.00 (dd, 1H, H-49a; JH49a,H49b 5 14.3 Hz, JH39,
H49a 5 9.9 Hz). 13C-NMR (1H decoupled, 50% vol/vol CD3CND20) 153.6 (C-7), 153.5 (C-6), 152.9 (C-2), 144.3 (C-3), 139.3 (C-9),
138.1 (C-10), 106.6 (C-8), 106.2 (C-5), 63.5 (C-49), 72.5 (C-39), 75.4
(C-29), 56.8 (C-6,7-MeO), and 39.3 (C-19); fast atom bombardment
mass spectrometry (glycerol matrix), (m 1 1)/z 5 295.
Measurement of intracellular D-lactate. Cytosolic fractions from
1.5 3 109 cells were deproteinized by adding perchromic acid (0.7 M).
After centrifugation, the supernatant was adjusted to pH 6.0 with 5 N
KOH followed by a second centrifugation. D-Lactate in the supernatant was measured using an HPLC method after conversion into
2-methylquinoxanol as described by Ohmori et al. (39). Briefly, to
0.5 ml of the supernatant, 300 ml of 0.1 M potassium phosphate, pH
1144
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7.7, and 50 ml of 52.5 mM hydrazine sulfate (Sigma Chemical Co.)
were added. The mixture was incubated for 30 min at 378C. 250 ml of
26 mM thioctamide, 50 ml of 62.5 U/ml of diaphorase (ICN Biomedicals, Inc., Irvine, CA), 50 ml of 25 mM NAD (Sigma Chemical Co.),
and either 50 ml of 500 U/ml of D-LDH (Sigma Chemical Co.) or 50 ml
of water were then added, and the incubations were continued for 2 h
at 378C. Then 238 ml of 35 mM O-phenylenediamine (Sigma Chemical Co.) and 0.3 ml of 1.5 N hydrochloric acid were added and allowed to react at 508C for 1 h with shaking. The reaction mixture was
adjusted to pH 3.0 with 2 M sodium phosphate and extracted with 2 ml
of ethylacetate twice. The ethylacetate layer was evaporated and redissolved in 0.5 ml of the mobile phase (10 mM potassium phosphate,
pH 2.9/acetonitrile [76:24]). HPLC was performed on a 5 mm C-18
column (Prodigy; Phenomenex Inc., Torrance, CA), 4.6 3 250 mm, at
a 1 ml/min flow rate and detected with UV detector (Dynamax; Rainin Instruments Co., Woburn, MA) at 334 nm (excitation wavelength
341 nm). The value of 2-methylquinoxanol incubated without D-LDH
was subtracted from the value with D-LDH.
Measurement of acetol. The assay was performed using a previously described method with slight modification (40). The same procedure was used for sample preparation as that used in the D-lactate
assay. The acetol derivative formed with 2,4-dinitrophenylhydrazine
was separated using a 5 mm, C-18 column (Spherex; Phenomenex,
Inc.), 250 3 4.6 mm, with a linear gradient elution with water and
methanol (initial conditions 55% methanol, 1 ml/min, final conditions
100% methanol, 2 ml/min) and detected with a UV/visible detector
(Dynamax; Rainin Instruments Co.) at 365 nm.

Results
High glucose (30 mM) does not affect glyoxalase-I activity in
GM7373 cells. To evaluate the effect of high glucose on glyoxalase-I activity in GM7373 cells, cells were incubated in
media containing either 5 or 30 mM glucose for 7 d. Then,
cytosolic fractions were extracted and glyoxalase-I activity was
determined. No significant difference in enzyme activity was
found between cells exposed to 5 and 30 mM glucose (0.696
0.01 vs. 0.6660.01 mmol/min/mg protein, n 5 3, P 5 NS).
A glyoxalase-I inhibitor, HCCG, enhances hyperglycemiainduced intracellular AGE formation in GM7373 cells. To evaluate the effect of glyoxalase-I inhibition on intracellular AGE
formation in GM7373 cells, cells were incubated in either 5 or
30 mM glucose, or 30 mM glucose containing 40 mM of a glyoxalase-I inhibitor, HCCG, for 4 d. The media were changed
every 12 h. Intracellular AGE formation in the cells exposed
to 30 mM glucose was increased 5.4-fold compared to 5 mM
(1.4060.08 vs. 0.2660.02 total absorbance units, n 5 3, P ,
0.001). This hyperglycemia-induced AGE formation was enhanced an additional 2.4-fold in the presence of the glyoxalase-I
inhibitor (3.2060.03 vs. 1.4060.08 total absorbance units, n 5 3,
P , 0.001).
Stable expression of human glyoxalase-I in GM7373 cells increases glyoxalase-I activity. To evaluate the effect of glyoxalase-I on intracellular AGE formation, a GM7373 endothelial
cell line stably expressing human glyoxalase-I activity was generated as described in Methods. The expression of human glyoxalase-I protein was demonstrated by Western blotting using
a polyclonal antibody against human glyoxalase-I. As shown in
Fig. 2 (lanes 3 and 4), a single band around 20 kD was detected, which corresponds to the molecular mass of the monomeric subunit of human glyoxalase-I (20,774 D) (26). To evaluate glyoxalase-I activity in transfected cells, glyoxalase-I
activity of cytosolic fractions was determined. The enzyme activity was increased about 28-fold in glyoxalase-I–transfected

centration, both glyoxal and 3-DG levels were below the statistical limit of detection (glyoxal; , 11 pmol/106 cells and 3-DG;
, 21 pmol/106 cells) (Table I).
Hyperglycemia-induced increased MG content is normalized by increased enzymatic reduction in glyoxalase-I–expressing GM7373 endothelial cells. Although MG content in neo
cells exposed to 30 mM glucose was increased by 181% compared with the cells exposed to 5 mM glucose (35.565.8 vs.
19.661.6 pmol/106 cells, P , 0.02), there was no significant difference in MG content between 30 and 5 mM glucose in glyoxalase-I–transfected cells (18.963.2 vs. 18.465.8 pmol/106 cells,
P 5 NS). We next measured D-lactate to evaluate the minimal
cumulative effect of high glyoxalase-I activity on MG metabolism in either 30 or 5 mM glucose for 7 d. D-lactate content in
neo cells in 30 mM glucose was increased 2.1-fold compared
with neo cells in 5 mM glucose (21.061.3 vs. 10.061.2 pmol/106
cells, n 5 3, P , 0.01). In contrast, in glyoxalase-I–transfected
cells, the hyperglycemia-induced D-lactate formation in 30 mM
glucose was markedly enhanced. D-lactate content was increased 11.4-fold compared to 5 mM glucose (107.168.9 vs.
9.460 pmol/106 cells, n 5 3, P , 0.001).
Acetol level in neo- and glyoxalase-I–transfected cells incubated in 30 mM glucose is not increased significantly. The enzyme aldose reductase catalyzes the conversion of MG to acetol (15). To evaluate the role of acetol in intracellular AGE
production, we measured the level of acetol in cells incubated
in either 5 or 30 mM glucose. The acetol levels in both neoand glyoxalase-I–transfected cells in either glucose concentration were equally low and there was no significant difference
between them (, 8.0 pmol/106 cells).
Glyoxalase-I expression in GM7373 endothelial cells reduces hyperglycemia-induced increases in macromolecular endocytosis. Both neo cells and glyoxalase-I–expressing cells
were incubated in either 5 or 30 mM glucose to evaluate the effect of glyoxalase-I on hyperglycemia-induced increases in endocytosis. The cellular endocytosis of horseradish peroxidase
in neo cells exposed to 30 mM glucose for 10 d was increased
2.2-fold compared with cells exposed to 5 mM glucose
(5.1260.14 AU/106 cells vs. 2.13860.02 AU/106 cells, n 5 3
P , 0.001), whereas the endocytosis in glyoxalase-I–transfected cells was not increased (2.2760.02 AU/106 cells vs.
2.2960.03 AU/106 cells, n 5 3, P 5 NS).

Figure 2. Western blot of human glyoxalase-I protein in
GM7373 cells. Lanes 1 and 2
are duplicates of neo-transfected cells. Lanes 3 and 4 are
duplicates of glyoxalase-I–transfected cells.

cells compared with neo-transfected cells (21.860.1 vs. 0.7660.02
mmol/min/mg protein, n 5 3, P , 0.001).
Glyoxalase-I expression in GM7373 endothelial cells reduces hyperglycemia-induced intracellular AGE formation, but
does not affect CML or CEL content. Both neo cells and glyoxalase-I–expressing cells were incubated in either 5 or 30 mM
glucose, to evaluate the effect of glyoxalase-I on hyperglycemia-induced intracellular AGE formation. AGE concentration in the cells was measured by dot blotting using an mAb
against AGE. After the cells were exposed to 5 and 30 mM
glucose for 7 d, cytosolic fractions were used for the measurement. Intracellular AGE formation in neo-transfected cells exposed to 30 mM glucose was increased 13.6-fold compared
with the cells exposed to 5 mM glucose (2.5860.15 vs.
0.1960.03 total absorbance units, n 5 3, P , 0.001), whereas
intracellular AGE in glyoxalase-I–transfected cells was not increased by 30 mM glucose (0.2560.03 vs. 0.2160.08 total absorbance units, n 5 3, P 5 NS). Analysis of two epitopes recognized
by the antibody 6D12, CML and CEL, showed no differences
between neo- and glyoxalase-I–transfected cells (CML: neo
cells, 0.012660.0010 mmol/mol lysine; glyoxalase-I–transfected
cells, 0.020160.0047 mmol/mol lysine, n 5 6, P 5 NS; CEL:
neo cells, 0.038760.0093 mmol/mol lysine; glyoxalase-I–transfected cells, 0.028660.0056 mmol/mol lysine, n 5 6, P 5 NS).
Glyoxal and 3-DG levels in endothelial cells are low and are
not increased significantly by 30 mM glucose. Glyoxal has been
identified as a key intermediate in the autoxidative modification of proteins by glucose (11). 3-DG also has been thought to
be an important intermediate in AGE formation in vivo (41,
42). We evaluated both glyoxal and 3-DG levels in both neoand glyoxalase-I–transfected cells incubated in either 5 or 30
mM glucose. In both cell types exposed to either glucose con-

Discussion
In this study we found that endogenous glyoxalase-I activity
was identical in GM7373 endothelial cells exposed to either 5

Table I. Effect of Glyoxalase-I on Glyoxal, MG, D-lactate, Acetol, and 3-DG Content in the neo- and Glyoxalase-I–transfected
Cells Exposed to Either 5 or 30 mM Glucose
Cells

neo
Glyoxalase-I

Glucose

Glyoxal
6

3-DG
6

MG
6

D-lactate
6

Acetol

mM

pmol/10 cells

pmol/10 cells

pmol/10 cells

pmol/10 cells

pmol/106 cells

5
30
5
30

, 11i
, 11
, 11
, 11

, 21i
, 21
, 21
, 21

19.661.6
35.565.8*
18.465.8
18.963.2

10.061.2
21.061.3‡
9.460
107.168.9§

, 8.0i
, 8.0
, 8.0
, 8.0

*P , 0.02 vs. neo 5 mM, ‡ P , 0.01 vs. neo 5 mM, § P , 0.001 vs. neo 5 mM, i below statistical limit of detection.
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or 30 mM glucose. As demonstrated previously (10), intracellular AGE concentration was increased by 30 mM glucose, as
was macromolecular endocytosis. This hyperglycemia-induced
intracellular AGE formation was significantly increased when
glyoxalase-I was partially inhibited by HCCG, providing indirect evidence that 30 mM glucose increased AGE formation
by generating MG. To examine directly the role of MG in hyperglycemia-induced intracellular AGE formation, GM7373
endothelial cells were generated that stably expressed human
glyoxalase-I with a 28-fold higher glyoxalase-I activity than
neo-transfected cells. In neo-transfected cells, 30 mM glucose
incubation increased MG and D-lactate concentration approximately twofold. In contrast, in glyoxalase-I–transfected cells,
30 mM glucose incubation did not increase MG concentration
at all, while increasing the terminal product of the glyoxalase
pathway, D-lactate, . 10-fold. Incubation of neo cells in 30 mM
glucose did not cause any change in the levels of glyoxal,
3-DG, or acetol, however, the measured levels were below
the statistical detection limits. Most strikingly, overexpression
of glyoxalase-I completely prevented hyperglycemia-induced
AGE formation, and also prevented hyperglycemia-induced
macromolecular endocytosis. These results indicate that hyperglycemia increases AGEs in GM7373 endothelial cells primarily, if not exclusively, by increasing the concentration of
AGE-forming MG, and that hyperglycemia-induced increases
in macromolecular endocytosis are a consequence of MG accumulation.
Intracellular glycation and AGE formation have been associated with low catalytic efficiency of aldehyde reductase in the
diabetic rat kidney (43) and decreased mitogenic activity of basic fibroblast growth factor (bFGF) in cultured endothelial
cells (10). After incubation of endothelial cells in 30 mM glucose for 168 h, AGE-modified bFGF was increased by 6.1-fold
and bFGF mitogenic activity was reduced by 70% (10). Our
finding that endogenous glyoxalase-I activity is unaffected by
these incubation conditions suggests that the lysyl residue in
the active site of mammalian glyoxalase-I (44) is not susceptible to modification by glucose, most likely because of its microenvironment (45).
Since MG has been associated with cellular toxicity (14),
preliminary experiments were performed to establish the optimum concentration of the glyoxalase-I inhibitor HCCG. This
competitive inhibitor of glyoxalase-I mimics the enediol intermediate associated with the glyoxalase-I reaction (18). At a
concentration of 80 mM, GM7373 cells died after 2 d, while at
40 mM HCCG, there was no cell death as assessed by trypan
blue exclusion. Thus the observed increase in hyperglycemiainduced AGE formation reflects MG produced by a partial
inhibition of glyoxalase-I. To ensure that the mAb 6D12 recognized MG-modified proteins, we demonstrated a concentration-dependent increase in the immunoreactivity of 6D12
against HSA minimally modified with highly purified MG in
vitro, when either protein or MG concentration was the independent variable (46). To determine whether the mAb 6D12
was in fact detecting changes in intracellular CML, MG-derived
CEL, or an unidentified MG-derived epitope, CML and CEL
were quantitated using gas chromatography/mass spectrometry in both neo- and glyoxalase-I–transfected cells. Since analysis of both CML and CEL content showed no differences between neo- and glyoxalase-I–transfected cells, it is likely that
the AGE formed by MG and recognized by 6D12 is a different
MG protein epitope.
1146

Shinohara et al.

Our finding that incubation in 30 mM glucose increases
concentrations of MG and its metabolite D-lactate in neotransfected cells is consistent with the finding that MG concentration is increased three- to fivefold in the blood of diabetic
patients (47). The lack of increase in MG concentration after
incubation of cells overexpressing glyoxalase-I in high glucose
and much greater increase in D-lactate are consistent with
greater enzymatic conversion of MG to its metabolite, and
suggest that glyoxalase-I activity is rate-limiting in hyperglycemia-induced increases in MG production. Intracellular concentrations of glyoxal and 3-DG were not detectable even after incubation in 30 mM glucose, suggesting that in these cells,
glucose autoxidation and Amadori product decomposition did
not occur to a significant degree. This conclusion is indirectly
supported by the observation that overexpression of glyoxalase-I, which does not utilize 3-DG as a substrate, completely
inhibited hyperglycemia-induced intracellular AGE formation. Elevated concentrations of 3-DG and its reduction product 3-deoxyfructose have been reported in blood from both
animal and human diabetics (41, 42), however, suggesting that
this intermediate may play a major role in extracellular AGE
formation and/or in intracellular AGE formation in other cell
types.
Acetol was also not detected even after incubation in 30 mM
glucose, suggesting that conversion of MG to this alternate
AGE precursor by aldose reductase (15) does not take place
to any significant extent in these cells. Thus aldose reductase
inhibitors are unlikely to increase intracellular AGE formation, and may even reduce MG formation by preventing the
redox-induced inactivation of glyceraldehyde 3-phosphate dehydrogenase (5) and by preventing the hyperglycemia-induced
depletion of the glutathione reductase cofactor NADPH (48).
The demonstration that hyperglycemia-induced intracellular AGE formation and increased macromolecular endocytosis in GM7373 endothelial cells result from increased MG production has important implications for the pathogenesis of
diabetic vascular complications. Diabetes induces increased
endothelial endocytosis in retinal capillaries in vivo, which
may contribute to the capillary pathology that subsequently
occurs (49).
Differences in the efficiency with which individual patients
detoxify MG may explain individual differences in susceptibility to complications, while elucidation of the biochemical
mechanisms by which hyperglycemia increases intracellular
MG concentrations may lead to novel therapeutic strategies.
Both of these possibilities deserve further exploration.
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